Serum free light chain level-based and non-fixed cycle daratumumab treatment strategy for patients with light chain amyloidosis
These findings indicate that the sFLC levels based and non-fixed cycle DARA strategy is an efficacious and safe treatment strategy in both newly diagnosed and relapsed/refractory AL amyloidosis.
Authors
- Wencui Chen (ORCID: https://orcid.org/0000-0001-6706-5237)
- Guisheng Ren
- Xianghua Huang (ORCID: https://orcid.org/0000-0002-0243-9426)
- Jinzhou Guo (ORCID: https://orcid.org/0000-0001-7530-4576)
- Liang Zhao (ORCID: https://orcid.org/0009-0002-7034-4231)
- Zhen Li (ORCID: https://orcid.org/0000-0002-5685-3163)
Institutions
- Nanjing General Hospital of Nanjing Military Command (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1080/07853890.2024.2442075
- Citations
- 2
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- National Natural Science Foundation of China